Drug comparisons
Alogliptin vs Nateglinide
Alogliptin vs Nateglinide for type 2 diabetes. Alogliptin is a once-daily DPP-4 inhibitor with lower hypoglycemia risk compared to the mealtime meglitinide Nateglinide.
No comparison dimensions are available for this page.
Clinical context
This comparison is relevant when selecting between a DPP-4 inhibitor and a meglitinide for managing type 2 diabetes, especially considering dosing frequency and hypoglycemia risk.
Bottom line
Alogliptin is typically preferred over Nateglinide in modern type 2 diabetes treatment for its ease of use and safety advantages.
All medication comparisons